Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Japanese Economy Threatened by “Serious Illness” New Keizai Doyukai Chairman Mr Hasegawa
May 16, 2011
- Actemra Approved for SJIA as Additional Indication in US
May 16, 2011
- Drug Makers to Continue Production through Golden Week
May 16, 2011
- Liovel, Nexium Recommended for Approval
May 16, 2011
- CHMP Gives Positive Opinion for Avastin, Xeloda Combination: Roche
May 16, 2011
- METI to Subsidize Installation of In-house Power Generators
May 16, 2011
- Simponi Recommended for Approval
May 16, 2011
- FDA Issues Complete Response Letter for Aricept Patch: Eisai
May 16, 2011
- Major Drugstore Chains to Hire More New Graduates from Disaster Areas
May 16, 2011
- Kyowa Kirin Files NDA for Anti-CCR4 Antibody KW-0761
May 16, 2011
- Gov't Has Not Yet Considered Postponing Medical, Nursing Fee Revision in 2012: Senior Vice Minister Ohtsuka
May 16, 2011
- Pfizer Allows Special Leave for Volunteers in Disaster Area
May 16, 2011
- Korosho to Create Council on Regulatory Strategies
May 16, 2011
- Discussion Starts to Revise Ethical GL for Genome Analysis
May 16, 2011
- Supreme Court Favors Patent Extension for Takeda's DDS Formulations
May 16, 2011
- Korosho Draws Up Draft Guidance for Risk Management Plans
May 16, 2011
- Kaketsuken, GSK Start PI Trial of New Cell Culture-based Flu Vaccine
May 16, 2011
- Production of Pravastatin Drug Substance to Resume in Sept.: Daiichi Sankyo
May 2, 2011
- Eisai's Halaven for Inoperable Breast Cancer
May 2, 2011
- Lixisenatide Reduces HbA1c in Combination with SU or SU + Metformin
May 2, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…